$17.33
+0 (+0%)
At Close: Sep 24, 2018
UK-based IT firm Noventiq scraps SPAC deal to list on Nasdaq
09:33am, Thursday, 04'th Jul 2024
July 4 (Reuters) - London-headquartered information technology firm Noventiq and special purpose acquisition company Corner Growth Acquisition have mutually agreed to terminate their blank-check deal,
Noventiq Appoints Huong Tran as new CFO for the Asia Pacific Region
07:00am, Monday, 20'th May 2024
LONDON--(BUSINESS WIRE)---- $COOL--Noventiq Holdings PLC (Noventiq), a leading provider of digital transformation and cybersecurity solutions and services, announces the appointment of Huong Tran as t
Noventiq Announces Strategic Joint Venture with Al-Suwaiket Group in Saudi Arabia
07:00am, Monday, 29'th Apr 2024
RIYADH, Saudi Arabia--(BUSINESS WIRE)---- $COOL--Noventiq Holdings PLC (Noventiq), a leading provider of digital transformation and cybersecurity solutions and services, announces a strategic joint ve
Noventiq Reports Third Quarter Fiscal 2024 Trading Update
08:10am, Wednesday, 03'rd Apr 2024
LONDON & PALO ALTO, Calif.--(BUSINESS WIRE)---- $COOL--Noventiq Holdings PLC (“Noventiq”), a global digital transformation and cybersecurity solutions and services provider, today announced unaudi
Noventiq Appoints Jerry Letter as Chief Financial Officer and Head of Corporate Development
07:55am, Wednesday, 03'rd Apr 2024
LONDON & PALO ALTO, Calif.--(BUSINESS WIRE)---- $COOL--Noventiq Holdings PLC (“Noventiq” or “the Company”), a global digital transformation and cybersecurity solutions and services provider, t
Noventiq Announces Strategic Joint Venture with Net One Asia in Singapore
08:35am, Monday, 25'th Mar 2024
SINGAPORE--(BUSINESS WIRE)---- $COOL--Noventiq Holdings PLC (Noventiq), a global leader in digital transformation and cybersecurity solutions and services provider, is excited to announce a strategic
Noventiq and Corner Growth Acquisition Corp. File Form F-4/A; Reports Strong H1 FY24 Results Ahead of Proposed Nasdaq Listing
05:33pm, Wednesday, 13'th Mar 2024
LONDON & PALO ALTO, Calif.--(BUSINESS WIRE)---- $COOL--Noventiq Holdings PLC (“Noventiq”), a global digital transformation and cybersecurity solutions and services provider, and Corner Growth Acqu
Noventiq and Corner Growth Acquisition Corp. File Form F-4 Ahead of Proposed Nasdaq Listing
06:00pm, Tuesday, 02'nd Jan 2024
LONDON & PALO ALTO, Calif.--(BUSINESS WIRE)---- $COOL--Noventiq Holdings PLC (“Noventiq”), a global digital transformation and cybersecurity solutions and services provider, and Corner Growth Acqu
Noventiq Launches Weaver Peer – the Indispensable AI Team Member for Business Growth
07:00am, Tuesday, 21'st Nov 2023
LONDON--(BUSINESS WIRE)---- $COOL--Noventiq, a global leading digital transformation and cybersecurity solutions and services provider, has announced the launch of Weaver Peer, a revolutionary knowled
Noventiq goes offshore to secure US SPAC deal
08:03am, Friday, 10'th Feb 2023
London-based IT firm Noventiq announced on Thursday that will list its shares in the US via a reverse merger deal with Corner Growth Acquisition Corp, a Nasdaq-listed special purpose acquisition compa
‘HOT NIGHTS, COOL TUNES’ RETURNS SATURDAY WITH TUNES FROM THE BRITISH INVASION – KWHI.com
10:21pm, Friday, 08'th Jul 2022
(courtesy Visit Brenham) Downtown Brenham will travel across the pond tomorrow (Saturday) night for its first “Hot Nights, Cool Tunes” concert of t...
PolarityTE''s SkinTE Meets Primary, Secondary Goals In Venous Leg Ulcers Trial
06:02pm, Tuesday, 22'nd Feb 2022 Benzinga
PolarityTE Inc (NASDAQ: PTE ) has announced results from a multi-center randomized controlled trial evaluating SkinTE for Venous Leg Ulcers (VLU). There were twenty-nine participants, with 14 receiving SkinTE plus standard of care (SOC) and 15 receiving SOC alone. 71% (10/14) of participants receiving SkinTE plus SOC had wound closure at 12 weeks versus 33% (5/15) of participants receiving SOC alone (p=0.046). Percent Area Reduction (PAR) assessed at 4, Full story available on Benzinga.com
PolarityTE stock rises 4% on getting US patent
01:59pm, Thursday, 17'th Feb 2022 Seeking Alpha
PolarityTE (PTE) received a patent from the U.S. Patent and Trademark Office for compositions that relate to the company''s minimally polarized functional unit ((MPFU)) technology…
PolarityTE gets US FDA clearance to begin phase 3 trial of SkinTE for chronic ulcers
08:11pm, Tuesday, 18'th Jan 2022 Seeking Alpha
PolarityTE (PTE) said the U.S. Food and Drug Administration approved its investigational new drug ((IND)) to begin a phase 3 trial of SkinTE to treat chronic cutaneous ulcers.In…
FDA Approves PolarityTE''s Phase 3 Study Of SkinTE In Chronic Cutaneous Ulcer
05:40pm, Tuesday, 18'th Jan 2022 Benzinga
The FDA has signed off PolarityTE Inc''s (NASDAQ: PTE ) investigational new drug (IND) application to evaluate SkinTE to treat chronic cutaneous ulcers. This follows the Company satisfactorily addressing clinical hold items that the FDA had previously identified. The approval enables PolarityTE to commence the … Full story available on Benzinga.com
Sign In
Buy COOL